Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy

Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy

Introduction There was no 13-valent pneumococcal conjugate vaccine (PCV13) adult antibody concentration threshold regulatory criterion for licensure – unlike the pediatric indication; consequently, for the adult indication, PCV13 serotype-specific opsonophagocytic activity (OPA) geometric mean titer...

Full description

Bibliographic Details
Main Authors: Mark A. Fletcher, Beate Schmoele-Thoma, Jelena Vojicic, Derek Daigle, Peter R. Paradiso, Graciela del Carmen Morales
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Expert Review of Vaccines
Subjects:
pneumococcal conjugate vaccine
adult
clinical trial
immunogenicity
safety
coadministration
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2024.2404636

Internet

https://www.tandfonline.com/doi/10.1080/14760584.2024.2404636

Similar Items